Table 2 CXCL5 expression correlated with clinicopathological characteristics analyzed by logistic regression
From: Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion
Characteristics | Total (N) | Odds ratio (OR) | p-Value |
|---|---|---|---|
T stage (T2 and T3 and T4 vs. T1) | 168 | 1.305(0.985–2.354) | 0.021 |
N stage (N1 vs. N0) | 172 | 3.447(1.568–3.889) | 0.386 |
N stage (N1 vs. N0) | 132 | 0.886(0.458–1.568) | 0.944 |
Pathologic stage (Stage III and Stage IV vs. Stage I and Stage II) | 128 | 1.251(0.986–2.033) | 0.158 |
Histologic grade (G3 and G4 vs. G1 and G2) | 176 | 1.748(1.048–2.355) | 0.018 |
Vascular invasion (Yes vs. No) | 158 | 1.528(1.088–2.417) | 0.048 |
AFP (ng/ml) (> 400 vs. ≤ 400) | 168 | 1.058(0.735–1.686) | 0.168 |
Albumin (g/dl) (≥ 3.5 vs. < 3.5) | 169 | 0.844(0.408–1.590) | 0.294 |
Tumor status (with tumor vs. tumor-free) | 172 | 1.568(1.120–2.322) | 0.318 |